|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal Susitarimą)
| (51) | INT.CL. | C07K 14/705 | |
| C07K 19/00 | |||
| C12N 5/10 | |||
| A61K 38/17 |
| (11) | Patento numeris | 1141248 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 99967350.2 |
| Europos patento paraiškos padavimo data | 1999-12-16 | |
| (97) | Europos patento paraiškos paskelbimo data | 2001-10-10 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2011-12-07 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US1999/029873 |
| Data | 1999-12-16 |
| (87) | Numeris | WO 2000/036092 |
| Data | 2000-06-22 |
| (30) | Numeris | Data | Šalis |
| 112752 P | 1998-12-17 | US |
| (72) |
BROWNING, Jeffrey, US
MIATKOWSKI, Konrad, US
MEIER, Werner, US
|
| (73) |
Biogen Idec MA Inc.,
14 Cambridge Center, Cambridge, Massachusetts 02142,
US
|
| (54) | A METHOD FOR THE HIGH LEVEL EXPRESSION OF THE ACTIVE FORM OF LYMPHOTOXIN-BETA RECEPTOR IMMUNOGLOBULIN FUSION PROTEINS AND THEIR PURIFICATION |
| A METHOD FOR THE HIGH LEVEL EXPRESSION OF THE ACTIVE FORM OF LYMPHOTOXIN-BETA RECEPTOR IMMUNOGLOBULIN FUSION PROTEINS AND THEIR PURIFICATION |